CURA Diagnostics has had an incredible year, marked by significant accomplishments and exciting new partnerships. As we wrap up this year and look forward to an even stronger start to the next, we are thrilled to introduce our new Vice President of Sales,

November 4th, 2024 – As Transversal Therapeutics (CURA owned subsidiary company) pursues non-dilutive funding opportunities in the drug toxicology space, we are excited to announce that we have recently received the notice of allowance for our patent appl

September 17th, 2024– As CURA enters the latter half of the year, we are pleased to announce the successful completion of our Pre-A series funding round. CURA has raised over $4 million, led by a prominent asset management firm. Underscoring strong confid

CURA is dedicated to building and sustaining strong partnerships, with a primary focus on delivering outstanding customer service and ensuring client satisfaction. As we continue to grow, we've successfully established enduring relationships on a glob

CURA Diagnostics is thrilled to announce their new partnership with Mercedes Scientific. As a leader in laboratory distribution, Mercedes Scientific has established itself as a top player in the industry through collaborations with leading diagnostic comp

CURA Diagnostics is very excited to announce another significant achievement! We have implemented our complete solution in Kentucky-based laboratory.The Laboratory has not only passed its state inspection but has done so flawlessly, without a single defic

CURA Diagnostics proudly announces the successful installation of our second A20 and complete laboratory solution at a new reference lab in Kentucky. This achievement underscores our commitment to delivering state-of-the-art solutions to advanced toxico

CURA Diagnostics has experienced a year of significant achievements and advancements. A standout among these triumphs has been the successful launch of A20 and comprehensive lab solutions, implemented across multiple laboratories. As we eagerly anticipa

Revolutionary Diagnostic System Ready for Routine Clinical Lab TestingCURA Diagnostics is thrilled to announce the successful installation of its groundbreaking A20 system at a U.S. client site. This achievement is a testament to the dedication and har

Strategic Move Marks a New Milestone in the Company's Rapid Growth.In a strategic move that underscores its commitment to global innovation and growth, CURA Diagnostics Inc. has announced the establishment of its second subsidiary company, CURA Diagno

We're thrilled to introduce Dr. Qian Cheng as the newest member of CURA Diagnostics, joining us as our Chief Scientific Officer. With over a decade of experience in the toxicology field, including eight years as a board-certified Clinical Laboratory D

The inauguration of CURA Diagnostics' state-of-the-art R&D lab in Woburn, MA, marks a pivotal moment for the company. This facility revolutionizes and optimizes CURA's operations, propelling them towards enhanced efficiency and innovation.The key

CURA Diagnostics Successfully Completes Oversubscribed Seed Round, Raising over $2M in Funds. Leading Innovator in Medical Diagnostics Gears Up for Commercialization. CURA Diagnostics, a trailblazing company in the field of medical diagnostics, has achieved a

CURA Diagnostics Unveils Xpeedy A20: Revolutionizing Automated Sample Preparation for LC/MS/MS AnalysisFirst Client to Implement Cutting-Edge Solution for Urine Toxicology Tests in AugustGreater Boston Area, July 21, 2023- CURA Diagnostics, Inc., a lead

CURA Diagnostics Acquires Transversal Therapeutics – Will Offer Innovative Sensor Technologies for Point-of-Care DevicesGreater Boston Area, June 16, 2023- In a groundbreaking move set to transform the landscape of point-of-care diagnostics, CURA Diagnost